Holen Sie sich die Stockscreener-App
4.1802
2.11%
-0.0898
Schlusskurs vom Vortag:
$4.27
Offen:
$4.33
24-Stunden-Volumen:
679.20K
Relative Volume:
0.92
Marktkapitalisierung:
$104.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.81M
KGV:
-
EPS:
-
Netto-Cashflow:
$-42.93M
1W Leistung:
-9.13%
1M Leistung:
-70.75%
6M Leistung:
-67.06%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.845
$4.33
1-Wochen-Bereich:
$3.845
$4.75
52-Wochen-Spanne:
$3.61
$24.00
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Vergleichen Sie ANRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ANRO | 4.1802 | 104.64M | 0 | -49.81M | -42.93M | 0.00 |
| VRTX | 450.09 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.09 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.68 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.62 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
What is William Blair's Forecast for ANRO FY2024 Earnings? - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - PR Newswire
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Alto Neuroscience, Inc. (ANRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Alto Neuroscience, Linkage Global, Pixie Dust: Top 3 Stocks With Explosive Retail Follower Growth Last Week - Barchart
Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Up 29.9% in October - MarketBeat
Q1 EPS Estimates for Alto Neuroscience Lowered by Wedbush - MarketBeat
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade - MSN
William Blair Has Negative Outlook for ANRO FY2028 Earnings - MarketBeat
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience sinks as ALTO-100 misses goal in MDD - The Pharma Letter
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Yahoo Finance
RODMAN&RENSHAW Lowers Alto Neuroscience (NYSE:ANRO) to Hold - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Alto depression drug failure sends shares plunging 66% - Green Market Report
Gold Moves Lower; AT&T Earnings Top Views - MSN
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
2024-10-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect | NYSE:ANRO | Press Release - Stockhouse Publishing
Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed - Investing.com
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade (NYSE:ANRO) - Seeking Alpha
Alto Hits The Wrong Note In Depression - Scrip
Alto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO) - MarketBeat
Alto Neuroscience shares PT slashed by Baird following ALTO-100 failure - Investing.com
Alto Neuroscience Stock Plummets Pre-Market After MDD Drug Trial Misses Primary Endpoint, Grabs Retail Attention - Barchart
Robert W. Baird Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $10.00 - MarketBeat
Alto hits new low as depression drug flunks key test - Yahoo Finance
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint - Clinical Trials Arena
Alto Neuroscience (NYSE:ANRO) Downgraded to "Neutral" at Wedbush - MarketBeat
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO - BioSpace
Alto Neuroscience reports setback in depression drug trial By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Trading 1.6% HigherShould You Buy? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Up 1.6% – Here’s What Happened - Defense World
Dow Tumbles Over 250 Points; Boeing Posts Q3 LossBoeing (NYSE:BA) - Benzinga
Alto Neuroscience stock craters 57% post-market on failed study - MSN
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):